Unregulated expression of wild-type BRCA1 (wtBRCA1) confers an altered phenotype in cultured human prostate cancer cells, characterized by chemosensitivity, susceptibility to apoptosis, decreased DNA repair activity, and alterations of key cell regulatory proteins. We now report that the expression of truncated or mutant full-length BRCA1 genes can abrogate certain phenotypic characteristics and/or confer the opposite phenotype to the wild-type BRCA1 gene. In particular, several carboxyl-terminal truncated BRCA1 proteins conferred chemoresistance, decreased susceptibility to apoptosis, and decreased ability to suppress in vivo tumor growth. These truncated BRCA1 proteins also blocked the ability of ectopically expressed wtBRCA1 to induce chemosensitivity and to inhibit estrogen receptor transcriptional activity. Studies using epitope-tagged truncated proteins con®rmed their expression, nuclear localization, and functionality. On the other hand, in cells with no endogenous wild-type BRCA1 (HCC1937 human breast cancer cells), the wtBRCA1 gene enhanced cellular DNA repair activity and rendered the cells resistant to DNA damage; while truncated BRCA1 proteins blocked the wtBRCA1-induced chemoresistance. Our ®ndings suggest that truncated BRCA1 proteins can inhibit the function of wild-type BRCA1. They raise the possibility that some inherited BRCA1 mutations may actively promote oncogenesis by blocking the function of the remaining wild-type BRCA1 allele, although this hypothesis remains to be proved. Oncogene (2001) 20, 8215 ± 8235.
Introduction
Mutations of the BRCA1 gene (17q21) confer a high risk for breast, ovarian, and prostatic cancers (Ford et al., 1994; Gayther et al., 1995; Miki et al., 1994; Streuwing et al., 1997) . BRCA1 encodes an 1863 amino acid (aa), 220 kDa nuclear phosphoprotein containing a conserved amino-terminal RING ®nger (zinc ®nger-like) domain that interacts with various cell cycle regulatory proteins (Holt et al., 1996; Chen et al., 1996b; Wang et al., 1997) and an acidic carboxyl-terminal transcriptional activation domain (TAD) (Monteiro et al., 1996) (see Figure 1a) . The over-expression of BRCA1 causes inhibition of cell growth and renders human cancer cells more susceptible to apoptosis Harkin et al., 1999) ; while decreased BRCA1 expression is linked to cell proliferation and transformation and is observed in sporadic breast cancers (Thompson et al., 1995; Rao et al., 1996; Taylor et al., 1998) . BRCA1 participates in the regulation of cell cycle progression (Chen et al., 1996b; Holt et al., 1996; Somasundaram et al., 1997; Fan et al., 1998; Aprelikova et al., 1999) , apoptosis Shao et al., 1996; Fan et al., 1998) , and DNA repair pathways (Abbott et al., 1999; Cortez et al., 1999; Gowen et al., 1998; Moynahan et al., 1999; Scully et al., 1997b,c) .
Breast cancers from patients with BRCA1 mutations have a 2 ± 3-fold higher frequency of chromosomal aberrations than do sporadic cancers (Tirkkonen et al., 1997) , suggesting a role for BRCA1 in the maintenance of genomic integrity. We found that BRCA1 inhibits the transcriptional activity of the estrogen receptor (ER-a) (Fan et al., 1999a) , in part via a direct interaction with the ER-a protein (Fan et al., 2001a) , suggesting a role for BRCA1 in the regulation of estrogen-stimulated mammary cell growth. The latter ®ndings also suggest a speci®c mechanism of breast cancer suppression of BRCA1.
Although tumor-associated point mutations of BRCA1 are observed within the highly conserved amino-terminal RING domain and the carboxylterminal TAD, most cancer-associated mutations are insertion-deletion type mutations that result in a frame shift error and protein truncation (Miki et al., 1994; Friedman et al., 1994; Gayther et al., 1995) . These truncation mutations can occur throughout the length of the BRCA1 protein, yielding carboxyl-terminal truncated mutant BRCA1 proteins of dierent sizes. These considerations raise the possibility that some of the proteins encoded by mutant BRCA1 genes are themselves oncogenic or that they oppose the functions of the wild-type BRCA1 allele. A role for mutant p53 proteins as inhibitors of wild-type p53 function or as directly acting oncoproteins has been established (Dittmer et al., 1993; Shaulian et al., 1992) . However, most p53 mutations are point mutations resulting in amino acid substitutions within the sequence-speci®c DNA-binding region (Runnebaum et al., 1991) . These mutations result in constitutively expressed full-length mutant p53 proteins that block the sequence-speci®c transactivational activity of the wild-type p53 protein.
Some of the functional activities of the BRCA1 protein have been attributed to physical and functional interactions between BRCA1 and other tumor suppressor proteins (e.g., p53 and the retinoblastoma (Rb) protein (Ouichi et al., 1998; Zhang et al., 1998; Aprelikova et al., 1999; Yarden and Brody, 1999) ) or oncogenic proteins (e.g., c-Myc ). Truncated BRCA1 proteins that retain the ability to mediate some of these protein interactions may, therefore, disrupt the function of the wild-type BRCA1 protein by sequestering important BRCA1-interacting proteins. In this manuscript, we tested this hypothesis by examining the phenotypes conferred by a series of mutant BRCA1 transgenes and the ability of these BRCA1 genes to modulate the functional activity of the full-length wild-type BRCA1. Our ®ndings suggest that some carboxyl-terminal truncated BRCA1 proteins may inhibit the functional activity of the fulllength wild-type BRCA1 protein.
Results

Expression of transfected BRCA1 genes
The set of BRCA1 transgenes utilized in this study are illustrated in Figure 1a . Stably transfected cell clones expressing each of these genes as well as empty pcDNA3 vector-transfected control (neo) clones were isolated after selection in G418. The expression of the dierent BRCA1 genes was con®rmed by semiquantitative RT ± PCR analysis, using three dierent primer sets to assess the expression of various BRCA1 mutant cDNAs, including truncation mutations, as described earlier (Fan et al., 2001a) . The three primer sets mapped to widely separated sites within the BRCA1 mRNA (see Figure 1a , bottom). Thus, comparisons of the relative amounts of the dierent ampli®ed cDNA segments with that of the controls (parental and neo cells) by densitometric analysis allow the detection of increased mRNA expression corresponding to the truncated or mutant BRCA1 genes ( Figure 1b) . The b-actin gene was used as a control for loading and for the basic PCR ampli®cation protocol.
As predicted, primer set #1 (which maps to the carboxyl-terminus of BRCA1) yielded increased levels of the 285-bp ampli®ed product in cells stably transfected with the wtBRCA1, 5677insA, or T300G Figure 2 In vitro proliferation of DU-145 cell clones stably transfected with dierent BRCA1 transgenes. Subcon¯uent proliferating cultures were harvested, and the cells were inoculated into 6-well dishes (3610 4 cells per well) on day 0. For each individual clone, duplicate wells were counted and the values were averaged. Cell number values are the means+ranges of the two clones of each type. Population doubling times (T d ) were calculated based on cell counts from days 1 ± 4; neo 15.8 h, wtBRCA1 20.4 h, T300G 16.3 h, 5677insA 21.1 h, DBamHI 16.9 h, DKpnI 18.3 h, DEcoRI 15.9 h, and 185delAG 16.5 h of the two clones of each type were examined for BRCA1 and a-actin, as a control for loading and transfer. Full-length or near fulllength transgenic proteins (wtBRCA1, 5677insA, T300G) were detected as an increase in the total quantity of the 220 kDa BRCA1 protein band, relative to control (neo) cell clones. The 88 kDa predicted BRCA1 DKpnI protein band was observed in the DKpnI but not neo clones. However, BRCA1 bands of the predicted M r for DBamHI (147 kDa) and DEcoRI (37 kDa) were not observed. The 185delAG protein (38 aa) is too small to detect. See text for further clari®cation. Note: Antibody C-20 (Santa Cruz Biotechnology) was used for blots of wtBRCA1, 5677insA, and T300G. A combination of monoclonals against the N-terminus of BRCA1 (Ab-1+Ab-2, Oncogene Research Products) was used to detect DBamHI, DKpnI, and DEcoRI. (d) Comparison of BRCA1 protein levels in various cell types. The BRCA1 levels in transfected DU-145 cell clones (Neo-2, 5677insA-9, wtBRCA1-2 and -6, T300G-3) were compared with the endogenous BRCA1 protein levels in untransfected human breast (MCF-7, MDA-MB-453, SK-BR-3) and cervical cancer (HeLa) cell lines. Equal aliquots of total cell protein were loaded (50 mg per lane). Note: The two BRCA1 bands represent the hypophosphorylated (lower M r ) and hyper-phosphorylated (higher M r ) forms of the protein, which are cell cycle dependent genes. However, mutations that truncate the BRCA1 mRNA 5' to the primer (DBamHI, DKpnI, and DEcoRI) failed to yield an increase in the 285-bp product, relative to untransfected or neo control cells (Figure 1b ). Primer set #2, which maps to the middle of the BRCA1 protein, yielded an increase in the 457-bp product in cells transfected with wtBRCA1, 5677insA, T300G, and DBamHI, all of which yield mRNAs that include the ampli®ed cDNA segment. In contrast, DKpnI and DEcoRI, which encode mRNAs truncated 5' to primer set #2, failed to yield an increase in the 457-bp product.
Primer set #3, which maps to the amino-terminus of BRCA1, gave increased 196-bp product in all but the control and 185delAG-transfected cells. The quantities of ampli®ed BRCA1 cDNAs were increased about 4 ± 5-fold, indicating increased expression of the BRCA1 expression plasmids. These ®ndings con®rm the expression of all BRCA1 mRNAs, except 185delAG, the expression of which was no dierent from the control cells. The 185delAG encoded mRNA appears to have a very short half-life. Because of the tiny size of the predicted protein product (38 aa), even if the 185delAG gene were expressed, it would be unlikely to Figure 3 Eect of stable transfection of dierent BRCA1 genes on chemosensitivity to the DNA damaging agent adriamycin (ADR). MTT assays of cell viability were performed utilizing a t=2 h (a) or t=24 h (b) exposure to ADR. For each individual cell clone, 10 replicate wells were assayed, and the values of cell viability were averaged. Values plotted are then means+ranges for two DU-145 cell clones of each clonal type. (c) Shows the ED 50 values (i.e., doses in mM, of ADR required to reduce cell viability to 50% of control) corresponding to the t=2 h and t=24 h exposures to ADR, respectively. When individual clonal responses were compared, it was found that wtBRCA1 and 5677insA clones were signi®cantly more sensitive to ADR then neo (P50.001), while DKpnI and DEcoRI clones were more resistant than neo (P50.0001) confer an altered phenotype. This frame-shift mutation probably behaves as a null mutation. Similarly, we were unable to detect expression of the 185delAG mutant in transient transfection assays (Fan et al., 2001a) .
BRCA1 protein expression was examined in two clones of each type by Western blotting, using a-actin, as a control for loading and transfer. Full-length or near full-length transgenic proteins (wtBRCA1, 5677insA and T300G) were detected as an increase in the total quantity of the 220 kDa BRCA1 protein band, relative to control (neo) cell clones or untransfected parent cells (Figure 1c ). The 88 kDa predicted BRCA1 DKpnI protein band was observed in the DKpnI but not neo clones. However, BRCA1 bands of the predicted M r for DBamHI (147 kDa) and DEcoRI (37 kDa) were not observed. The 185delAg protein (38 aa) is too small to detect. The failure to detect the DBamHI and DEcoRI proteins is probably due to technical problems with antibodies directed against BRCA1 amino-terminal epitopes, since expression of truncated BRCA1 proteins was demonstrated in subsequent studies of FLAG-tagged BRCA1 proteins. Finally, transfection with genes coding for Figure 4 Susceptibility of DU-145 cell clones transfected with dierent BRCA1 cDNAs to apoptosis induced by the DNA damaging agent adriamycin (ADR). Subcon¯uent proliferating cells (two clones of each type) were treated with ADR (15 mM 6 24 h), washed, post-incubated for 24 h in fresh drug-free culture medium, and then harvested for extraction of low molecular weight DNA and agarose gel electrophoresis. Ethidium bromide stained gels were photographed under ultraviolet illumination. For each individual gel, the bottom panel provides quantitation of the total intensity of the DNA ladders (relative to the neo controls), obtained using the UN-SCAN-IT image and gel software package (Silk Scienti®c Inc., Orem, UT, USA). The relative DNA ladder intensities are expressed as means+ranges corresponding to the two clones representing each type signi®cantly truncated BRCA1 proteins (DBamHI, DKpnI, DEcoRI, and 185delAG) did not result in obvious changes in the level of the endogenous 220 kDa BRCA1 protein.
In Figure 1d , we compared the BRCA1 protein levels in several transfected DU-145 cell clones (5677insA, wtBRCA1, and T300G) with the endogenous BRCA1 in levels in several human breast cancer cell lines (MCF-7, MDA-MB-453, and SK-BR-3) and a cervical cancer cell line (HeLa). This comparison shows that the BRCA1 protein levels in the BRCA1-transfected DU-145 cell clones are the same as or less than the BRCA1 levels observed in the other untransfected cell types. In fact, the endogenous BRCA1 levels in MCF-7 and SK-BR-3 cells appear to be somewhat higher than the BRCA1 levels in any of the transfected DU-145 cell clones. These ®ndings suggest that the BRCA1 protein levels achieved in stably transfected DU-145 cell clones are of the same order of magnitude as the endogenous BRCA1 levels expressed by other cell types. However, with in an individual cell type such as DU-145, any increase in BRCA1 levels above the baseline endogenous levels undoubtedly could contribute to phenotypic alterations.
In vitro cell proliferation
We compared the growth rates of DU-145 cell clones stably transfected with the set of dierent BRCA1 transgenes illustrated in Figure 1a , in DMEM supplemented with 5% fetal calf serum (Figure 2 ). Under these experimental conditions, control (neo) clones and most of the mutant/truncated BRCA1 clones showed similar growth kinetics, with population doubling times (T d ) ranging from 16 ± 18 h; while the wtBRCA1 and 5677insA clones grew a little more slowly, with T d % 20 ± 21 h. Thus, the in vitro growth rates were only slightly aected by the stable expression of dierent BRCA1 genes. Consistent with this study, in two previous reports, we found that wtBRCA1 clones of DU-145 grew relatively well in vitro, but showed slightly longer doubling times than did parental cells and control (neo) clones (Fan et al., , 2001b . In agreement with the results obtained for stable wtBRCA1-transfected DU-145 cell clones, we found that MCF-7 and T47D wtBRCA1 stable cell clones grew slightly more slowly (i.e., slight increase in T d ) than did parental cells and neo clones (data not shown). The implications of these ®ndings are considered in the Discussion.
Chemosensitivity of DU-145 cells stably transfected with mutant BRCA1 genes
To compare the eects of various BRCA1 genes on chemosensitivity, subcon¯uent proliferating cells were exposed to the DNA topoisomerase IIa inhibitor adriamycin (ADR), post-incubated in drug-free culture medium for 72 h, and assayed for cell viability using the MTT assay (Alley et al., 1988) . This assay is based on the ability of intact mitochondria to reduce a tetrazolium salt to formazan. Control-transfected (neo) clones were used as negative controls and wtBRCA1-transfected cell clones were used as positive controls, to characterize the wtBRCA1 phenotype. As were reported earlier, clones transfected with wtBRCA1 (= aa 1 ± 1863) or 5677insA, which encodes a slightly truncated protein (= aa 1 ± 1852), were more sensitive to ADR than the neo clones (Figure 3 ). In contrast, clones transfected with more highly truncated BRCA1 genes, DEcoRI (= aa 1 ± 302) and DKpnI (= aa 1 ± 1771) were more chemoresistant than neo clones (Figure 3a ± c). Clones transfected with DBamHI (= aa 1 ± 1313) or with T300G, which encodes a fulllength BRCA1 protein with a point mutation in the amino-terminal RING ®nger domain ( 61 Cys?Gly), exhibited similar chemosensitivity to neo clones.
Like DU-145, wtBRCA1-transfected T47D and MCF-7 cell clones were signi®cantly more chemosensitive than the corresponding neo clones. Thus, in tests of three clones of each clonal type, the ED 50 values were: T47D (neo 410 mM ADR; wtBRCA1 % 1 mM ADR) and MCF-7 (neo 4.9 mM ADR; wtBRCA1 0.9 mM ADR). Since DU-145 cells have mutant p53 and Rb (Sarkar et al., 1992) , while T47D cells have mutant p53 and wild-type Rb and MCF-7 cells are Co gamma rays (900 cGy), post-incubated for 24 h, and then subjected to alkaline elution to measure single strand breaks (SSBs) or neutral elution to measure double strand breaks (DSBs). Values represent the per cent of DNA eluted (minus that of untreated controls), mean+range for two dierent clones of each clonal type. Note: Irradiation was performed at 258C using a dose rate of 100 cGy per min wild-type for both of these genes (Watts et al., 1995) , these ®ndings suggest that the ability of wtBRCA1 to induce chemosensitivity is not dependent upon the p53 or Rb functional status of the cells. Figure 6 Alterations in cellular regulatory proteins in DU-145 clones expressing wild-type vs mutant BRCA1. Subcon¯uent proliferating cultures of two clones of each clonal type were harvested and subjected to Western blotting for dierent regulatory proteins, as described earlier . Equal aliquots of total cell protein (50 mg per lane) were electrophoresed; and the protein bands were detected by enhanced chemiluminescence (a). To assess the susceptibility to apoptosis, proliferating cells were exposed to ADR, then incubated for 24 h in fresh drug-free medium, after which low molecular weight DNA was isolated and subjected to agarose gel electrophoresis (Herrmann et al., 1994) . Apoptosis is detected by the presence of a pattern of interologonucleosomal sized DNA fragments (`DNA ladders'). The intensities of the DNA ladders were quantitated by computerized densitometry and expressed relative to that of the control (neo) cells. The results of these assays ( Figure 4) were consistent with the chemosensitivity assays shown in Figure 3 . Thus, DU-145 clonal types that were chemoresistant (DEcoRI and DKpnI) showed less apoptosis than control cells; while cloncal types that were chemosensitive (wtBRCA1 and 5677insA) showed more apoptosis compared with control cells.
In agreement with the chemosensitivity assays, clonal types that showed no alterations of chemosensistivity (DBamHI, 185delAG, and T300G) showed similar susceptibility to ADR-induced apoptosis as the control cells. Similarly, MCF-7 wtBRCA1 cell clones were more susceptible to the induction of apoptosis by DNA-damaging agents, as compared with MCF-7 neo cell clones (data not shown).
DNA strand break assays
We used DNA ®lter elution assays to compare the number of residual DNA strand breaks present in the dierent DU-145 clonal types at T=24 h after exposure to ADR or to 60 Co gamma radiation. The responses to ADR and radiation were generally similar. Clonal responses were grouped into clone types that showed similar numbers of residual single-strand (SSBs) and double-strand breaks (DSBs) as compared with neo (185delAG, T300G, DBamHI), fewer breaks than neo (DEcoRI and DKpnI), and more breaks than neo cells (wtBRCA1 and 5677insA) ( Figure 5 ). These ®ndings correlated well with the results observed in the chemosensitivity and apoptosis assays. Thus, the same mutants that conferred chemoresistance (DEcoRI and DKpnI) also conferred a reduction in DNA strand breakage. The mutants that failed to alter chemosensitivity (T300G, DBamHI, and 185delAG) also failed to alter DNA strand breakage; while wtBRCA1 and 5677insA conferred chemosensitivity and increased DNA strand breakage.
It is noted here that the DNA ®lter elution assay requires relatively high doses of ADR to induce a measurable number of single strand breaks (SSBs) and even higher doses to induce double strand breaks (DSBs). While more modest doses of ADR (e.g., 5 mM) are sucient to observe dierences in chemosensitivity using the MTT assay, such doses yield insucient numbers of SSBs or DSBs to assess dierences in the ®lter elution assay. A caveat in the interpretation of the data is that at the very high ADR dose used to induce DSBs (30 mM62 h), the vast majority of the cells are destined to die. Although there was a signi®cant reduction in SSBs and DSBs induced by either ADR or gamma radiation in DU-145 cells transfected with Figure 7 Ability of dierent BRCA1 genes to rescue repression of ER-a transcriptional activity by wtBRCA1 in transient transfection assays. Transient transfection of the wtBRCA1 cDNA suppresses ER-a transcriptional activity, as indicated by loss of estradiol (E2)-stimulated, ER-a mediated activation of the estrogen-responsive luciferase reporter ERE-TK-Luc (Fan et al., 1999a) . We tested the ability of the dierent BRCA1 genes ( Figure 1a ) to`rescue' (i.e., reverse) the inhibition of E2-stimulated, ER-a mediated ERE-TK-Luc activity by wtBRCA1. Luciferase activity was expressed relative to the negative control (i.e., no E2). In the absence of a transfected BRCA1 gene (no vector or empty pcDNA3 vector), the relative luciferase activity (+E2) was about 2000; while the presence of wtBRCA1, the relative luciferase activity (+E2) was reduced to near the -E2 control (i.e., % 1). The white bars show the ERE-TK-Luc activity in the absence of wtBRCA1; and the dark bars show the ERE-TK-Luc activity when dierent BRCA1 genes were co-transfected along with the wtBRCA1 gene. Assays were performed as described in the Materials and methods section, using 0.25 mg of each indicated vector. Values are the means+s.e.m. of four replicate wells. The results shown are representative of several independent experiments truncated forms of BRCA1 (DEcoRI and DKpnI), some of this dierence could simply be due to higher cell survival in those cells.
Alterations in cell regulatory protein expression
We previously reported that DU-145 wtBRCA1 and 5677insA cell clones showed a spectrum of protein alterations, as compared with parental cells and neo clones: e.g., ; p300, ; Bcl-2, ; Bax, : BRCA2, ; p21 WAF1/CIP1 , and ; Mdm-2 . Here, we compared the alterations in protein levels in dierent DU-145 BRCA1 mutant clone types, to determine if the protein alterations could explain the observed dierences in chemosensitivity and susceptibility to apoptosis induction. As compared with the control (neo) cell clones, none of the other clonal types except wtBRCA1 and 5677insA exhibited any obvious alterations in levels of the regulatory proteins tested ( Figure  6 ). Thus, clonal types that exhibited chemoresistance and resistance to apoptosis induction (DEcoRI and DKpnI) showed similar levels of these proteins, as compared with the control (neo) clones and clonal types that showed no alterations of chemosensitivity or susceptibility to apoptosis (DBamHI, T300G, and 185delAG).
Rescue of the wtBRCA1 inhibition of ER-a signaling by mutant BRCA1 genes
We previously studied the ability of dierent BRCA1 genes to inhibit ER-a transcriptional activity and found that of the genes tested, only wtBRCA1 and 5677insA signi®cantly inhibited estrogen stimulated, ER-a Parental DU-145 cells were transfected with dierent doses of wtBRCA1 or 5677insA plasmid overnight at the indicated dose (mg of plasmid DNA per well) in 6-well dishes and assayed for cell viability following exposure to ADR (10 mM 6 2 h), as follows. Methodology. Proliferating cells in 100 mm dishes at about 60% of con¯uency were transfected overnight with 10 mg of each BRCA1 vector, washed, and incubated for 24 h in fresh culture medium to allow expression of the transfected genes (all in the presence of 2 mg/ml of TCN). Transfected cells were then harvested using trypsin and inoculated into 96-well dishes, still in the presence of TCN. After allowing attachment and recovery, cells were treated with ADR for 2 h, followed immediately by washing and incubation in the absence (7) or presence (+) of TCN. Dishes were post-incubated for 48 h, after which they were assayed for MTT dye conversion. Values are means+s.e.m. of 10 replicate wells Oncogene Mutant BRCA1 genes antagonize wild-type BRCA1 S Fan et al mediated activation of an estrogen-responsive reporter (ERE-TK-Luc) (Fan et al., 2001a ). Here, we tested the ability of the dierent BRCA1 mutant genes to`rescue' (i.e., reverse) the wtBRCA1-mediated repression of ER-a transcriptional activity, using transient transfection assays and the ERE-TK-Luc assay system. The ERE-TK-Luc reporter consists of the vitellogenin A2 estrogen-responsive enhancer element (ERE) upstream of a minimal thymidine kinase promoter (TK81) and the ®re¯y luciferase gene (Henttu et al., 1998) . A wildtype ER-a expression vector was co-transfected along with ERE-TK-Luc, since DU-145 cells lack endogenous ER-a. The assay end-point is the relative luciferase activity: i.e., the estradiol (E2)-stimulated, ER-a mediated ERE-TK-Luc activity, normalized to the activity observed in the absence of added E2.
As noted above, by themselves, only wtBRCA1 and 5677insA caused signi®cant inhibition of ER-a activity in DU-145 cells. However, three carboxyl-terminal truncated BRCA1 proteins (DBamHI, DKpnI, and DEcoRI) signi®cantly rescued the wtBRCA1-mediated inhibition of E2-stimualted ER-a activity (see Figure  7 ). On the other hand, the T300G mutant, a mutation of the RING domain that also abrogates the ability of BRCA1 to inhibit ER-a activity, failed to rescue the inhibition of ER-a by the wtBRCA1 gene.
Reversal of wtBRCA1-mediated chemosensitivity by certain mutant BRCA1 genes
In view of the ®nding that certain genes encoding truncated BRCA1 proteins reversed a functional activity of wtBRCA1 (i.e., repression of ER-a activity), we also tested the ability of our panel of mutant BRCA1 genes to reverse the increased chemosensitivity to the DNA-damaging agent ADR induced by wtBRCA1. The dierent mutant BRCA1 genes were transiently transfected into DU-145 cell clones containing the full-length wtBRCA1 cDNA down-stream of a tetracycline (TCN)-regulated (Tet-O) promoter. Figure 8a shows that following removal of TCN from the culture medium, BRCA1 mRNA and protein levels are increased in the DU-145/Tet-O/BRCA1 clones but not in the control (DU-145/Tet-O/Neo) cell clones. As in the case of the stably transfected DU-145 cell clones, the levels of BRCA1 protein achieved in the DU-145/Tet-O/BRCA1 clones following the removal of TCN was no higher than the endogenous BRCA1 protein levels in two human breast cancer cell lines (MCF-7 and SK-BR-3) (Figure 8a) . Thus, the BRCA1 expression levels achieved using the Tet-O promoter system do not appear to be`excessively' high.
Consistent with the assays of stably transfected DU-145 cell clones, assays performed in the presence of TCN (+TCN) revealed that transient expression of the BRCA1 DKpnI and DEcoRI genes resulted in increased cell viability following exposure to ADR; while increased expression of wtBRCA1 induced by the removal of TCN from the culture medium ( ± TCN) caused a reduction of cell viability (see control and empty vector (pcDNA3) transfected cells in Figure 8b ).
Assays performed under ± TCN conditions revealed that the same BRCA1 genes that induced resistance to ADR under +TCN conditions (DKpnI and DEcoRI) also inhibited the increased chemosensitivity to ADR caused by the over-expression of wtBRCA1 in the absence of TCN. Thus, the set of carboxyl-terminal truncated BRCA1 genes capable of reversing the wtBRCA1-mediated chemosensitivity (DKpnI and DEcoRI) was not identical to the set of BRCA1 genes that reversed the wtBRCA1-mediated inhibition of ERa activity (DBamHI, DKpnI and DEcoRI).
Theoretically, the reversal of the wtBRCA1-induced chemosensitivity by truncated BRCA1 proteins should require a high transfection eciency, since presumably all DU-145/Tet-O/BRCA1 cells will over-express wtBRCA1 when TCN is removed. To assess transfection eciencies, we have co-transfected control plasmid pRSV-b-gal (encoding a bacterial b-galactosidase gene) along with wild-type or mutant BRCA1 constructs Figure 10 Transient expression of wtBRCA1 causes chemoresistance in HCC1937 human breast cancer cells, that is reversed by the co-expression of carboxyl-terminally truncated BRCA1 genes. (a) Induction of resistance to ADR by wtBRCA1 transgene, demonstrated by MTT assays. Cells were transfected overnight with the indicated vector, and then assayed for sensitivity to ADR, using the MTT cell viability assay, as described above. Both the wtBRCA1 vector and the Tag-wtBRCA1 vector (but not the controls) induced increased survival of ADR-treated HCC1937 cells. Cell viability values are then means+s.e.m. of 10 replicate wells. (b) wtBRCA1 enhances the repair of ADR-induced DNA strand breaks in HCC1937 cells. Cells were transfected overnight with the indicated vector and assayed for ADR-induced DNA strand breaks as described above. Consistent with the results shown in (a), cells transfected with Tag-wtBRCA1 showed a reduction in the number of SSBs and DSBs at t=24 h after exposure to ADR. (c) Tag-wtBRCA1-mediated chemoresistance is blocked by Tag-truncated BRCA1 mutants. Assays were performed as in (a), except that the eects of individual as well as co-transfections were tested. None of the truncated Tag-BRCA1 proteins signi®cantly altered the chemosensitivity of the HCC1937 cells. However, Tag-BRCA1 DEcoRI, -DKpnI, and -DBamHI each blocked the ability of TagwtBRCA1 to mediate chemoresistance to ADR. Note: For each transfection condition tested, including the empty Tag vector control, the total amount of transfected DNA was kept constant by the addition of empty Tag vector under the same conditions used in these experiments. These studies have shown: (1) uniformly high quantitative levels of b-galactosidase enzymatic activity (determined spectrophotometrically); and (2) a very high percentage of b-galactosidase positive cells (determined by X-gal staining), usually over 95%. In previous studies, transfection eciencies were found to be similarly high, using the same transfection methods and the control plasmid pRSV-b-gal (see Fan et al., 2001a) . Although not all cells stained darkly, some bgalactosidase positivity was found in the vast majority of cells.
Since the 5677insA gene, a breast cancer-associated mutation, caused similar biologic responses to wtBRCA1, we performed a plasmid dose-response assay, to compare the eects of 5677insA vs wtBRCA1 on cell viability following exposure to ADR. In sideby-side comparisons, wtBRCA1 was more ecient at inducing sensitivity to ADR. The ED 50 values for cell viability were about 4.6 times higher for 5677insA (%4.2 mg/ml) than for wtBRCA1 (%0.9 mg/ml) ( Figure  8c ). Thus, while the 5677insA gene exhibits wtBRCA1 activity in this assay, it is quantitatively de®cient as compared with the full-length protein.
Expression, localization, and functionality of FLAGtagged truncated BRCA1 proteins Three carboxyl-terminal truncated BRCA1 proteins (DBamHI, DKpnI, and DEcoRI) reversed some of the biologic activities of wtBRCA1, as described above. However, of these three BRCA1 proteins, it was only possible to demonstrate the presence of DKpnI (88 kDa) by Western blotting (Figure 1c) . To con®rm the expression, cellular localization, and biologic function of these proteins, the cDNAs were ligated into an expression vector (Tag2) containing an aminoterminal FLAG sequence, to facilitate detection of the proteins using an anti-FLAG antibody. As shown in Figure 9a , in DU-145 cells transiently transfected with Tag-wtBRCA1, -DBamHI, -DKpnI, or -DEcoRI, proteins of the expected sizes were detected using an anti-FLAG antibody: ca. 220, 147, 88 and 37-kDa, respectively. In contrast, these proteins were not detected in control cells transfected with the Tagempty vector. Thus, each BRCA1 protein was detectable in transient expression assays.
To assess the localization of these tagged proteins, cells were transiently transfected and immunoperoxidase stained, using anti-FLAG as the primary antibody. In each case, strong immunostaining was detected in the nucleus, whereas untransfected cells or cells transfected with the Tag-empty vector showed little or no staining (see Figure 9b ). In comparison with the controls, there did appear to be some staining in the cytoplasm of cells transfected with Tag-DKpnI or Tag-DEcoRI, suggesting that the smaller BRCA1 fragments may also show some cytoplasmic localization. However, the majority of the FLAG staining appeared to be nuclear. The implications of these ®ndings are considered later, in the Discussion section.
To con®rm the function of the truncated Tag-BRCA1 proteins, DU-145/Tet-O/BRCA1 cells were transiently transfected with the dierent Tag-BRCA1 vectors, incubated+TCN, and assayed for sensitivity to ADR, using the MTT assay. As shown in Figure 9c , Tag-DKpnI and Tag-DEcoRI (but not empty vector) Figure 11 Eect of dierent BRCA1 genes on the in vivo growth of DU-145 clonal tumors. Cells were injected into the subcutaneous tissues of male nude mice at 3610 6 cells per injection, two injections per animal, ®ve animals per clone (= 10 injections per clone). Two clones of each clonal type were tested. Since clones of the same type yielded similar sized tumors, the data from the two individual clones were pooled. Tumor volumes are means+s.e.m. of all the injections that yielded tumors. The dierent clonal types were tested in three separate experiments (a ± c). Statistical comparisons of the mean tumor volumes for the dierent clonal types were made using the two-tailed t-test: (a) (wtBRCA1 or 5677insA or DKpnI) vs Neo, P50.001; 185delAG vs Neo, P40.1; DKpnI vs wtBRCA1, P50.001. (b) wtBRCA1 vs Neo, P50.001; (T300G or DEcoRI) vs Neo, P40.1 up to day 20 and P50.01 from day 21 ± 34. (c) (wtBRCA1 or DKpnI) vs Neo, P50.001; DKpnI vs wtBRCA1, P50.001
Oncogene Mutant BRCA1 genes antagonize wild-type BRCA1 S Fan et al strongly inhibited the wtBRCA1-induced chemosensitivity to ADR. Tag-DBamHI also reduced the chemosensitivity of ( ± TCN) cells, but to a much smaller extent than Tag-DKpnI or Tag-DEcoRI. Since the Tag-DBamHI protein was well expressed (Figure  9a ), similar to Tag-DEcoRI and Tag-DKpnI, these ®ndings suggest that DBamHI is weaker than the others in its ability to block wtBRCA1 chemosensitivity. It is not likely that the function of truncated BRCA1 proteins were due to changes in levels of endogenous full-length BRCA1, since Tag-DBamHI, -DKpnI, and -DEcoRI transfected cells showed no obvious changes in the levels of non-tagged full-length 220 kDa BRCA1 protein, detected by a carboxylterminal anti-BRCA1 antibody (Figure 9a ). In contrast, cells transfected with Tag-wtBRCA1 showed increased total levels of 220 kDa BRCA1, detected by anti-BRCA1 antibody, which detects both TagwtBRCA1 and the endogenous BRCA1.
To assess the ability of truncated BRCA1 proteins to alter BRCA1 protein interactions, we tested the eect of Tag-DEcoRI on the association of the endogenous full-length BRCA1 protein with cyclin D1, in parental DU-145 cells. The cells were transfected with Tag-DEcoRI (vs empty vector, as control), incubated for 24 h to allow expression of the transgene, and harvested for immunoprecipitation (IP)-Western blotting. A combination of antibodies against amino-plus carboxyl-terminal epitopes of BRCA1 (Ab-1 + Ab-2 + Ab-3) immunoprecipitated both endogenous full-length BRCA1 and Tag-DEcoRI proteins. As expected, an antibody against the carboxyl-terminal 20 aa of BRCA1 (C-20) immunoprecipitated only the endogenous (220 kDa) BRCA1 protein (Figure 9d ). Tag-DEcoRI and control transfected cells showed similar quantities of cyclin D1 in the (Ab-1 + Ab-2 + Ab-3) IP. However, Tag-DEcoRI transfected cells showed signi®cantly less cyclin D1 than control cells in the C-20 IP. These ®ndings suggest that the DEcoRI fragment of BRCA1 disrupts the association of the endogenous full-length BRCA1 protein with cyclin D1.
Wild-type BRCA1 induces chemoresistance that is reversed by co-expression of mutant BRCA1 genes in HCC1937 human breast cancer cells Several reports suggest that BRCA1 enhances DNA repair activity in cells lacking functional wild-type BRCA1 (Gowen et al., 1998; Abbott et al., 1999) . To reconcile our ®ndings ± which show that wtBRCA1 sensitizes DU-145, MCF-7, and T47D cells to DNA damaging agents ± with these reports, we tested HCC1937, a human breast cancer cell line with a single mutant BRCA1 allele (5382insC). In contrast to DU-145, MCF-7, and T47D, transient transfection of wtBRCA1 into HCC1937 cells caused increased resistance to ADR, indicated by increased cell viability of ADR-treated cells in MTT assays ( Figure  10a ) and decreased numbers of residual DNA strand breaks at 24 h in DNA ®lter elution assays ( Figure   10b ). These ®ndings suggest that in a background in which there is no endogenous functional BRCA1, an exogenous wild-type BRCA1 gene exerts cytoprotective activity with respect to cell survival and DNA repair.
If the hypothesis that truncated BRCA1 mutants such as DEcoRI and DKpnI (and in some assays DBamHI) antagonize the function of the full-length wild-type BRCA1, then it is expected that expression of these genes would have little or no eect on the chemosensitivity of a cell line that lacks endogenous wild-type BRCA1. On the other hand, co-expression of these genes with wtBRCA1 might be expected to block the ability of the full-length wtBRCA1 gene to induce chemoresistance. To test these hypotheses, we transiently transfected HCC1937 cells with combinations of Tag-wtBRCA1 plus Tag-truncated BRCA1 genes and determined the sensitivity to ADR, using the MTT cell viability assay.
None of the Tag-vectors caused toxicity; and cell viability was similar (% 21 ± 27%) in cells transfected with vehicle only, Tag-empty vector, -DEcoRI, -DKpnI, and -DBamHI (Figure 10c ). Cells transfected with Tag-wtBRCA1 alone were signi®cantly more resistant to ADR (cell viability % 45%); but the cotransfection of Tag-DEcoRI, -DKpnI, or -DBamHI along with Tag-wtBRCA1 caused an increase in sensitivity toward the control levels. It is noted that the -DBamHI vector did not reverse wtBRCA1-induced chemosensitivity in DU-145 cells, while the Tag-DBamHI vector did reverse wtBRCA1-induced chemoresistance in HCC1937 cells. The lack of eect of DBamHI in DU-145 chemosensitivity assays could be due to insucient protein expression, since it was noted that DBamHI did oppose the eects of wtBRCA1 in ER-a transcription assays.
In vivo tumor growth
We examined the growth of the dierent DU-145 clonal types as tumors in the subcutaneous tissue of male nude mice. A sucient number of cells was injected to ensure a nearly 100% tumor take rate, so that these assays assessed the tumor growth rate rather than the tumor forming ability (tumorigenicity) of the cells. Since the nude mice tested over an interval of time exhibited some degree of variation in the growth rates of the control (neo) tumors, all assays included a negative control (neo tumors) and a positive control (wtBRCA1 tumors). The relative tumor growth was only compared within an individual experiment utilizing the same batch of animals.
In all experiments, wtBRCA1 tumors grew signi®-cantly more slowly than all of the other clonal types (P50.001, two-tailed t-tests). In the experiments shown in Figure 11a ,b, the growth of wtBRCA1 and 5677insA tumors during the experimental period (ca. 5 weeks) was very slow; while the other clonal types tested (neo, 185delAG, DEcoRI, DBamHI, and T300G) grew at similar rates up to day 20. From day 21 ± 34, the DEcoRI and T300G tumors continued to grow rapidly, although the growth rates were slightly slower than that of the neo tumors (P50.01) (see Figure 11b ). The growth rates of the DBamHI and 185delAG clones did not dier signi®cantly from that of the control (neo) clones. As illustrated in Figure 11a ,c, the BRCA1 DKpnI tumors grew more slowly than the neo tumors (P50.001), but more rapidly than the wtBRCA1 tumors (P50.001).
Discussion
These studies revealed the dierential eects of a series of BRCA1 transgenes on dierent phenotypic characteristics of DU-145 human prostate cancer cells. As reported previously, wtBRCA1 caused a slight reduction of in vitro cell growth, a marked increase in sensitivity to adriamycin and susceptibility to adriamycin-induced apoptosis, a characteristic set of protein alterations (e.g., decreased levels of p300, Bcl-2, Bax, p21, and Mdm-2) and suppression of ER-a transcriptional activity (Fan et al., , 1999a (Fan et al., , 2001a . Despite only a small reduction of the in vitro growth rate (increase in population doubling time (T d ) from 16 to 20 h), wtBRCA1 transfected DU-145 cell clones displayed a substantial reduction of in vivo growth as subcutaneous tumors in nude mice. This ®nding suggests an in vivo tumor growth suppression activity of wtBRCA1 that is not entirely predictable based on the in vitro cell proliferation characteristics.
We have described the relatively small degree of growth inhibition of DU-145 cells stably transfected with wtBRCA1 in several prior publications 2001b ); and we found very similar eects in stable wtBRCA1 clones of breast cancer cell lines MCF-7 and T47D. While a growth inhibitory function of wtBRCA1 is well known (Holt et al., 1996; Somasundaram et al., 1997) , there is also evidence suggesting an additional growth stimulatory activity. Thus, a Brcal homozygous deletion in mice caused early embryonic lethality (by day 8.5), due to a severe cellular proliferation defect (Hakem et al., 1996) . BRCA1 is expressed cyclically, with maximum levels and phosphorylation during late G1 and earlymiddle S phase (Chen et al., 1996b; Vaughn et al., 1996; Rajan et al., 1997) . And when cells were induced to exit the cycle (e.g., due to serum starvation), BRCA1 levels went down; and BRCA1 was re-expressed when the cells all went back into the cycle and entered S (Rajan et al., 1997) . Finally, our study showed the DU-145 wtBRCA1 cell clones exhibit constitutive activation of Jak-Stat3 signaling, inhibition of which leads to growth inhibition (Gao et al., 2001) . These considerations lead us to postulate that the lack of strong in vitro suppression of DU-145 cell growth by wtBRCA1 re¯ects a balance of inhibitory and stimulatory eects on cellular proliferation.
The stable expression of two BRCA1 genes (DEcoRI and DKpnI) conferred chemoresistance and resistance to apoptosis induction, as compared with control (neo) DU-145 cell clones. This ®nding suggests that certain BRCA1 mutations may not only abrogate BRCA1 functional characteristics, but may also interfere with the function of the endogenous wild-type BRCA1. Multiple observations, when interpreted collectively, strongly support the contention that truncated BRCA1 proteins can function as dominant inhibitors of the full-length wild-type protein. These observations include the following:
(1) In cells with endogenous BRCA1 (DU-145) , the stable expression of DEcoRI and DKpnI proteins caused a phenotype (chemoresistance and resistance to apoptosis) opposite to that of wtBRCA1. Observations 4 and 5 may be particularly relevant, because they suggest that the ability of the DEcoRI and DKpnI proteins to alter chemosensitivity requires the presence of a functional full-length BRCA1 protein.
While there is strong evidence that some truncated BRCA1 proteins inhibit the phenotype conferred by wtBRCA1, the implications of this ®nding for the biology of BRCA1 mutant cancer development need to be ®rmly established. These studies would include examination of the in vivo expression of the wild-type BRCA1 allele relative to truncating BRCA1 mutations in non-cancerous human cells heterozygous for the BRCA1 mutation. It must further be established whether or not the endogenous mutant truncated BRCA1 proteins oppose the wild-type BRCA1 protein in these heterozygous human cells under natural conditions.
The eects of the panel of BRCA1 genes on wtBRCA1-mediated chemosensitivity and apoptosis susceptibility diered somewhat from their eects on wtBRCA1 suppression of ER-a activity. Thus, DBam-HI partially rescued the wtBRCA1 inhibition of ER-a activity but either failed to alter cellular chemosensitivity or had only a minimal eect on wtBRCA1-mediated chemosensitivity. Two other truncated BRCA1 genes (DEcoRI and DKpnI) induced chemoresistance and rescued the BRCA1 inhibition of ER-a activity.
The protein alterations in DU-145 cells, some of which can in¯uence chemosensitivity (e.g., ;p300, ;Bcl-2 and ;Bax), were observed only in wtBRCA1 and 5677insA clones. These changes may, in part, explain the wtBRCA1 and 5677insA mediated chemosensitivity. However, the levels of these proteins were similar in DEcoRI, DKpnI, and neo clones. The induction of chemoresistance by these truncated BRCA1 proteins is probably best explained by the disruption of protein: protein interactions involving the endogenous full-length BRCA1. The failure of the full-length BRCA1 mutant T300G ( 61 Cys?Gly) to induce any alteration in chemosensitivity suggests that one of these interactions involves the amino-terminal RING domain of BRCA1.
We have addressed the underlying mechanisms of BRCA1-mediated repression of ER-a transcriptional activity in details elsewhere (Fan et al., 2001a) . In that study, we found that the amino-terminal region of BRCA1 (within aa 1 ± 302) binds directly to the carboxyl-terminal activation domain (AF-2) of ER-a and that the carboxyl-terminus of BRCA1 is also required for inhibition of ER-a activity. We postulated that BRCA1 acts to recruit transcriptional co-repressor proteins (e.g., histone deacetylases, Rb, CtIP (carboxylterminal interacting protein)/CtBP (carboxyl-terminal binding protein)), which are known to interact with the carboxyl-terminus of BRCA1 (Yarden and Brody 1999; Yu et al., 1998) , to the ER-a transcriptional complex. This model would explain how DEcoRI, DKpnI, and DBamHI are able to rescue the wtBRCA1-mediated inhibition of ER-a activity, by binding to the receptor and displacing wtBRCA1, thus preventing the recruitment of co-repressors.
The reduced ability of DBamHI to modulate chemosensitivity, coupled with its ability to rescue ER-a activity, suggests a dissociation between the BRCA1 interactions that regulate chemosensitivity and ER-a activity. Speci®cally, these ®ndings suggest that a domain located between the KpnI and BamHI restriction sites (aa 772 ± 1313) in¯uences chemosensitivity. This region contains a site required for the association of BRCA1 and the DNA recombinase Rad51 (Scully et al., 1997b) , but is not required for the BRCA1 interaction with ER-a (Fan et al., 2001a) . Alternatively, the BRCA1 DBamHI protein levels may not be sucient to in¯uence cellular chemosensitivity, although they are sucient to disrupt wtBRCA1 repression of ER-a.
In a recent study, human breast cancer cell line HCC 1937 ± which has a single mutant BRCA1 allele (5382insC) ± was found to exhibit increased radiosensitivity, as compared with other breast cell lines containing one or two wild-type BRCA1 alleles (Abbott et al., 1999) . The increased radiosensitivity was restored to normal by transient transfection of either of two internally deleted BRCA1 genes (BRCA1 D 702 ± 834 or D 512 ± 1284). The eects wtBRCA1 and several other deletion mutants could not be assessed because these gene products suppressed colony formation, which was required for the assay. The BRCA1 D 702 ± 834 mutant also corrected a defect in transcription-coupled DNA repair in HCC1937 cells.
The ability of ectopic wild-type BRCA1 to induce growth suppression, chemosensitivity, and susceptibility to apoptosis has been described in cell types that contain functional BRCA1 (Holt et al., 1996; Fan et al., 1998; Harkin et al., 1999) . Conversely, the ability of ectopic wild-type BRCA1 to mediate DNA repair has been documented in cells lacking endogenous functional BRCA1, including HCC1937 and Brcal ( ± / ± ) mouse ®broblasts (Gowen et al., 1998; Abbott et al., 1999) . Therefore, we also tested the eects of wtBRCA1 and truncated mutant BRCA1 cDNAs in HCC1937 cells. In these cells, the transfection of a wtBRCA1 gene, but not truncated BRCA1 genes (DBamHI, DKpnI, or DEcoRI) rendered the cells more resistant to ADR and enhanced the rate of DNA strand break rejoining. By themselves, none of the truncated BRCA1 proteins had a signi®cant eect on chemosensitivity. However, each truncated protein inhibited wtBRCA1-induced chemoresistance of HCC1937, consistent with their ability to act as dominant inhibitors of wtBRCA1. These observations suggest that truncated BRCA1 proteins do not alter chemosensitivity in the absence of the full-length BRCA1, but rather counteract the eects of endogenous or transfected wtBRCA1.
They further suggest that the net activity of the fulllength wtBRCA1 transgene depends upon the genetic background of the cell: especially, whether or not the cell contains endogenous functional BRCA1. In BRCA1 null cells or cells with a single mutant BRCA1 allele (e.g., HCC1937), the wtBRCA1 gene enhances DNA repair and cell survival, while the opposite occurs in cell types containing functional wild-type BRCA1 (e.g., DU-145, MCF-7 and T47D). We postulate that cells normally regulate BRCA1 to the optimal levels required for survival and proliferation when they are cultured in vitro in the presence of fetal calf serum. These levels may be lower (as in DU-145) or higher (as in MCF-7 and SK-BR-3) depending upon the individual genetic background of the particular cell line. As a corollary, the non-physiologic up-regulation or loss of BRCA1 compromises cell survival in the setting of DNA damage. The mechanism(s) underlying the dierent responses to the wtBRCA1 gene in cells with and without endogenous BRCA1 is unclear. We speculate that disruption of physiologic protein: protein interactions occur either when BRCA1 is absent or expressed in non-physiologically high quantities. Some of these critical protein interactions probably involve transcriptional regulation, since the presence of BRCA1 within high molecular weight transcription complexes has been established (Scully et al., 1997a; Bochar et al., 2000) .
One mechanism by which truncated BRCA1 proteins may inhibit the function of the full-length protein is by disruption of protein ± protein interactions. Although we do not know which interactions mediate the regulation of chemosensitivity, the amino-terminus of BRCA1 interacts with a variety of cell cycle regulatory proteins, including cyclins, cyclin-dependent kinases, E2F family transcription factors, and another cell cycle-regulated RING domain protein called BARDI (Wu et al., 1996; Wang et al., 1997 Wang et al., , 1999 . In another study, we found that BRCA1 associates with and binds directly to cyclin D1, through a site located within the ®rst 300 aa of BRCA1 (submitted for publication). Here, we found that the expression of DEcoRI, which codes for aa 1 ± 302 of BRCA1, disrupted the ability of BRCA1 to associate with cyclin D1 in vivo. This ®nding suggests that small fragments of BRCA1 may disrupt molecular interactions of the full-length protein.
Studies using FLAG vectors revealed that all three truncated BRCA1 proteins (DBamHI (aa 1 ± 1313), DKpnI (aa 1 ± 771), and DEcoRI (aa 1 ± 302)) localized to the nucleus, although lesser but signi®cant degrees of cytoplasmic localization were also detected. The DEcoRI fragment lacks the primary nuclear localization signal (501 ± 507) that interacts with a-importin and mediates BRCA1 nuclear import (Chen et al., 1996a) . However, this fragment may enter the nucleus bound to other proteins that contain canonical nuclear localization signals. For example, the binding sites of other nuclear localizable proteins are found within aa 1 ± 302 of BRCA1, including BARD1, cyclin D1, cMyc, and ER-a (Wu et al., 1996; Wang et al., 1997 Wang et al., , 1999 Fan et al., 2001a) .
Many features of nuclear entry and exit are still not well understood. Clearly, the classic NLS and the hSRP1a (importin-a) NLS receptor complex are not the only mechanisms of nuclear entry, just as the nuclear export signal is not the only means of nuclear exit. For example, cyclin D1 has a classical NLS motif, yet it is present in the nucleus only during the G1 and appears to be actively excluded during other phases of the cell cycle (Lukas et al., 1994) . How cyclin D1 exits the nucleus and what makes it come back into the nucleus during the next G1 are not known. Since BRCA1 is present in supra-molecular (megadalton) transcription complexes (Scully et al., 1997a; Bochar et al., 2000) , and since components of these complexes exhibit multiple protein interactions with their neighbors, it would not be surprising if the DEcoRI protein were to become trapped in such complexes. This is especially true, since this fragment includes a RING ®nger domain, a region that is commonly found in transcription factors and other transcriptional regulatory proteins.
The ®nding that BRCA1 mutant breast cancers show a higher frequency of chromosomal aberrations (e.g., deletions) than sporadic cancers suggests a role for BRCA1 in the maintenance of genomic integrity (Tirkkonen et al., 1997) . This role could be accomplished if BRCA1 functions, in part, to activate an apoptosis program in cells that have accumulated a threshold level of unrepaired genomic damage. Our ®ndings are consistent with this view. And they suggest that the presence of certain truncating mutations of BRCA1 may enhance the ability of damaged cells to evade apoptosis, by inhibiting the function of the wildtype BRCA1 allele. With regard to this potential caretaker' function, BRCA1 was found to interact directly with p53 and to enhance p53 sequence-speci®c transcriptional activity (Ouichi et al., 1998; Zhang et al., 1998) . However, the ability of wtBRCA1 to induce susceptibility to apoptosis was observed in cells with mutant (DU-145 and T47D) as well as wild-type (MCF-7) p53, suggesting that this activity does not require a functional p53 protein.
BRCA1 has also been shown to interact directly with the Rb tumor suppressor protein, through two dierent binding sites: one within the carboxylterminal transcriptional activation domain (Yarden and Brody, 1999) and one located amino-terminally, between aa 300 and 394 (Aprelikova et al., 1999; Fan et al., 2001b) . One of these studies (Aprelikova et al., 1999) provided evidence that the growth suppressive activity of BRCA1 was mediated, in part, through the Rb protein. Since BRCA1-mediated chemosensitivity and susceptibility to apoptosis were observed in cell lines with mutant (DU-145) as well as wild-type (MCF-7 and T47D) Rb genes, these BRCA1 functions apparently do not require a functional Rb protein.
In our assay systems, the phenotype conferred by the 5677insA gene ± which encodes a protein missing the last 11 aa ± was similar to that conferred by wtBRCA1. This and other exon 24 mutations are linked to breast but not ovarian cancer (Friedman et al., 1994; Gayther et al., 1995) . We do not know if 5677insA confers a risk for prostate cancer. Thus, cell-type speci®city (prostate vs breast) could account for the retention of the wtBRCA1 phenotype in the 5677insA Du-145 cell clones. However, in a plasmid dose-response comparison of 5677insA vs wtBRCA1, we found that in transient transfection assays of DU-145 cells, a fourfold higher dose of 5677insA was required to achieve the same levels of sensitivity to ADR as wtBRCA1. We had reported that at low plasmid doses, a ®vefold higher dose of 5677insA was required to produce the same degree to repression of ER-a as wtBRCA1 in breast and prostate cancer cells (Fan et al., 2001a) . Although we did not compare protein levels at each plasmid DNA dose, we note the following: (1) wtBRCA1 vs 5677insA mRNA and protein levels were similar in stably transfected DU-145 cell clones; and (2) even if the 5677insA mRNA or protein were intrinsically less stable than the wtBRCA1 protein (which we do not believe is the case), the plasmid dose response data are still valid. If the 5677insA mRNA/protein were less stable than the wtBRCA1 protein, the same should be true in human BRCA1 heterozygous cells in patients. Thus, there appear to be quantitative dierences in the expression or activity of 5677insA, as compared with wtBRCA1.
Several DNA damaging agents, including ADR, can inhibit the expression of BRCA1 mRNA and, possibly, in¯uence protein degradation (Andres et al., 1998; Fan et al., 1999b) . Thus, BRCA1 mRNA levels are reduced within 4 ± 8 h after ADR exposure, and the protein levels decline after 16 ± 24 h. These DNA damage-induced alterations of BRCA1 mRNA and protein levels occur well after initial alterations in BRCA1 phosphorylation state (i.e., hyper-phosphorylation during S phase) and subnuclear localization that occur within 51 h of various forms of damage (Scully et al., 1997c; Cortez et al., 1999) . The BRCA1 phosphorylation in response to DNA damage is thought to re¯ect DNA damage signaling. This hypothesis supported by the identi®cation of a speci®c site on BRCA1 that is phosphorylated through the nuclear DNA damage signaling kinase ATM (ataxia-telangiectasia mutated) (Cortez et al., 1999) . These observations raise several possibilities: (1) wtBRCA1-mediated chemosensitivity of cells with endogenous functional BRCA1 is related to excess stimulation of DNA damage signaling, resulting in the activation of apoptosis pathways; and (2) that persistence of ectopic BRCA1 during the hours and days following DNA damage induces inappropriate transcriptional responses, leading to increased cellular damage and death. In this regard, further studies are required.
In conclusion, our ®ndings suggest that carboxylterminal truncated BRCA1 proteins can antagonize the function of the full-length wild-type protein. The results suggest that some tumor-associated BRCA1 mutations that cause protein truncation may result in the inhibition of the function of the wild-type BRCA1 allele.
Materials and methods
Sources of reagents
Adriamycin (ADR) (doxorubicin hydrochloride) was purchased from the Sigma Chemical Co. (St Louis, MO, USA). The primary antibodies used for Western blotting and their sources have been described elsewhere . MTT dye (thiazotyl blue) was obtained from Sigma.
Expression vectors and reporters
The wild-type BRCA1 expression plasmid (wtBRCA1) was created by cloning the BRCA1 cDNA into the pcDNA3 mammalian expression vector (Invitrogen) using arti®cially engineered 5' HindIII and 3' NotI sites. Mutant and truncated BRCA1 expression vectors were created by modi®cation of the wtBRCA1 cDNA in the pcDNA3 vector. The wild-type and mutant BRCA1 cDNAs were provided by Michael Erdos (National Human Gene Research Institute, Bethesda, MD, USA). In some experiments, wild-type and mutant BRCA1 cDNAs were expressed in vector pCMV-Tag2 (Stratagene), which allows expression of the protein with an aminoterminal FLAG sequence.
The expression vector pCMV-ER-a (ER-a) was used to express ER-a. The estrogen-responsive reporter plasmid ERE-TK-Luc is composed of the vitellogenin A2 estrogenresponsive enhancer (ERE) controlling a minimal thymidine kinase promoter (TK81) and luciferase, in plasmid pGL2 (Henttu et al., 1998) .
Cell culture and transfection
Human prostate cancer (DU-145) and breast cancer (MCF-7, T47D, HCC1937) cells were originally obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 5% fetal calf serum, Lglutamine (5 mM), non-essential amino acids (5 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml). For stable transfections, DU-145 cells in 100 mm dishes at 30 ± 40% of con¯uence were incubated overnight with 5 mg of plasmid, using Lipofectamine (Life Technologies), according to the manufacturer's instructions. Cells were selected in G418 (0.5 mg/ml). G418-resistant colonies were isolated using cloning rings, expanded, and screened by Western blot and RT ± PCR assays. Clones that stably over-expressed BRCA1 were frozen in liquid nitrogen. For transient transfections, proliferating cells in 100 mm dishes were incubated overnight with 10 mg of plasmid DNA in Lipofectamine and then washed.
Semi-quantitative RT ± PCR analysis
The mRNA expression of each BRCA1 transgene was evaluated by semi-quantitative RT ± PCR assays, using three dierent sets of PCR primers to distinguish transgenic from endogenous mRNA transcripts. The detailed methodology for these assays is described elsewhere (Fan et al., 2001a) . The locations of these primers is illustrated in Figure 1a . The BRCA1 primer sequences (5'?3') and the locations within the cDNA sequence (GenBank accession number U15595 (Miki et al., 1994) ) were as follows:
primer #1 sense TGG GGG GAG GAA AAT GGG TAG TTA antisense GAA GTA GTA AGT GGG AAC CGT GT bp 5239 to 5525 (285-bp product) primer #2 sense GAG TAA CAA GCC AAA TGA ACA G antisense TGG ATA CTT AAA GCC TTC TGT G bp 2159 to 2616 (457-bp product) primer #3 sense AAG GAA CCT GTC TCC ACA AAG T antisense GTC AAG CTG AAA AGC ACA AAT G bp 213 to 408 (196-bp product) The primers for the control gene b-actin were: sense TTG TTA CCA ACT GGG GAC GAT A antisense TCG TCC TTC TAG TTC TAG bp 265 to 1028 (764-bp product) In vitro cell proliferation Subcon¯uent proliferating cultures of two clones of each clonal type were harvested using trypsin. The cells were counted and inoculated into 6-well culture dishes at 3610 4 cells per well in 5.0 ml of growth medium (DMEM plus 5% fetal calf serum) on day 0. For each individual clone tested, duplicate wells were counted by hemacytometer on days 1 ± 8. The duplicatese cell counts agreed to within +5% of the mean values.
MTT assay of cell viability
MTT assays of cell viability were performed as described before Alley et al., 1988) . This assay is based on the ability of viable cells to convert MTT, a soluble tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) into an insoluble formazan precipitate, which is quantitated by spectrophotometry following solubilization in dimethyl sulfoxide. Brie¯y, subcon¯uent proliferating cells in 96-well dishes were treated with cytotoxic drugs in standard growth medium, washed, and then post-incubated for 72 h in fresh drugfree growth medium. At this time, the cells were solubilized and absorbance readings were taken using a Dynatech 96-well spectrophometer. The amount of MTT dye reduction was calculated based on the dierence between absorbance at 570 and 630 nm. Cell viability was expressed as the amount of dye reduction relative to that of untreated control cells.
Apoptosis assays
Subcon¯uent exponentially proliferating cells in 100 mm plastic Petri dishes were treated without or with drug (adriamycin) in standard growth medium; washed twice; incubated in fresh drug-free culture medium for 24 h; and then counted. Samples were normalized by cell number (500 000 ± 750 000 cells); and the low molecular weight apoptotic DNA was extracted, as described before Herrmann et al., 1994) . The DNA was electrophoresed through 1.2% agarose gels containing 0.1 mg/ml of ethidium bromide; and the gels were photographed under ultraviolet illuminated.
DNA filter elution assays
Exponentially growing cells were labeled with 3 H-thymidine (0.02 mCi/ml632 h); chased for 2 h in fresh isotope-free culture medium; exposed to dierent doses of drug or radiation; washed twice; incubated in fresh drug-free culture medium for various times; and counted. Equal numbers of cells (2610 6 ) were loaded onto polycarbonate ®lters, lysed, and subjected to alkaline elution or neutral elution, as described before Bertrand and Pommier, 1995) . Radioactivity in the DNA fractions was counted; and the fraction of DNA eluted was calculated as elution fraction/(®lter + lysis + elution fraction). Elution of DNA under alkaline conditions re¯ects the presence of single-strand breaks (SSBs); while elution under neutral conditions re¯ects double-strand breaks (DSBs).
In vivo tumor growth
For each cell line tested, subcon¯uent proliferating cells in 150 cm 2 culture dishes were harvested and counted; and a cell suspension containing 3610 6 cells in 0.15 ml or a 50:50 mixture of DMEM plus Matrigel (Collaborative Research) was prepared. Four to six-week-old male athymic nude mice were injected subcutaneously with 3610 6 cells per injection, two injections per animal (on the right and left sides), 10 animals per cell clone, and two cell clones per clonal type (= 20 injections per clonal type). Tumor volumes were measured twice per week by determining three mutually perpendicular diameters using calipers. Since the two individual clones of each type gave a very similar distribution of tumor sizes, these data were pooled for analysis of tumor sizes.
The volume of each tumor was calculated according to the formula V (in 
Estrogen receptor (ER-a) transcriptional assays
ER-a transcriptional activity was determined measuring the estrogen-stimulated, ER-a mediated activation of the estrogen-responsive reporter plasmid ERE-TK-Luc. Assays were performed essentially as described earlier (Fan et al., 1999a) . Brie¯y, asynchronously proliferating cells at about 50 ± 70% of con¯uency in 24-well dishes were incubated overnight with 0.25 mg of each vector in serum-free DMEM containing Lipofectamine. Cells were then washed, incubated in serumfree phenolphthalein-free DMEM (0.2 ml per well) without or with 17b-estradiol (E2, 1 mM) for 24 h, and harvested for luciferase assays. Luciferase values are means+s.e.m. of four replicate wells, and are representative of several independent experiments.
Tetracycline (TCN)-regulated BRCA1 expression system
The TCN-regulated expression system was created using the Tet-O system (Clonetech) (Freundlieb et al., 1997) which has two components: (1) regulator plasmid pTet-O, which expresses a fusion of the Tet repressor (TetR) and VP16 activation domain of herpes simplex virus under the control of the strong immediate early CMV promoter; and (2) response plasmid pTRE, which contains the Tet-responsive element (TRE) (seven copies of the 42-bp Tet operator) upstream of the minimal immediate early CMV promoter and a multicloning site. DU-145 cell clones were established by two separate stable transfections, ®rst plasmid pTet-O and secondly plasmid pTRE with the wtBRCA1 cDNA cloned into its multicloning site (pTRE-BRCA1). Double stable DU-145/Tet-O/BRCA1 cell clones were screened for BRCA1 expression induced by removal of TCN, by semiquantitative RT ± PCR analysis and by Western blotting (Fan et al., 2001b) .
Immunoprecipitation (IP) and Western blotting
For IPs, subcon¯uent proliferating cells in 150 cm 2 dishes were harvested, and nuclear extracts were prepared, as described earlier (Fan et al., 2001a,b) . Each IP was carried out using 6 mg of antibody or antibody combination and 1000 mg of nuclear extract protein. Precipitated proteins were collected using protein G beads, washed, eluted in boiling Laemmli sample buer, and subjected to Western blotting. The BRCA1 IP antibody was as follows: (1) combination of Ab-1 (MS110, Cat. #OP92)+Ab-2 (MS13, Cat. #OP93)+Ab-3 (SG11, Cat. #OP94), mouse monoclonals, Oncogene Research Products/Calbiochem; or (2) C-20 (Santa Cruz Biotechnology). Ab-1 and Ab-2 are reactive against epitopes in the amino-terminus of BRCA1; while Ab-3 and C-20 are reactive against carboxyl-terminal epitopes. The control IP antibody was normal mouse IgG.
Protein isolation and antibody sources and dilutions for Western blotting are the same as described earlier . To detect FLAG-tagged BRCA1 proteins, cells were Western blotted using mouse monoclonal anti-FLAG antibody M2 (Stratagene), at a dilution of 1 : 500. In each experiment, equal aliquots of total cellular protein (50 mg per lane) were electrophoresed and blotted. Proteins were detected using the enhanced chemiluminescence (ECL) detection system (Amersham). The protein bands were quantitated by densitometry and expressed relative to the 43 kDa a-actin band as a control for loading and transfer.
It is noted here that we utilized anti-BRCA1 antibody C-20 (Santa Cruz) to detect full-length forms BRCA1 (wild-type and mutant) or total BRCA1 (endogenous plus FLAG-tagged). This antibody was raised against the carboxylterminal 20 amino acids of BRCA1 and may cross-react with the epidermal growth factor receptor (EGF-R). BRCA1 Western blots were performed using 4 ± 5% polyacrylamide gels and including a high M r marker (range 204 ± 213 kDa). Under these conditions, it is easy to distinguish BRCA1 (which migrates at about 220 kDa) from the EGF-R, which migrates at 185 kDa. The same methodology has been used in previous studies (Fan et al., , 2001a . As illustrated in the Western blot in Figure 9a , endogenous wild-type BRCA1 detected by C-20 migrates at the same M r as FLAGtagged wtBRCA1 detected by the anti-FLAG antibody.
Data analysis
Where appropriate, statistical comparisons were made using the two-tailed Student's t-test.
